

Karim Dorgham

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2173984/publications.pdf>

Version: 2024-02-01

69
papers

8,322
citations

159358

30
h-index

91712

69
g-index

88
all docs

88
docs citations

88
times ranked

15175
citing authors

#	ARTICLE	IF	CITATIONS
1	Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs. <i>Science Immunology</i> , 2023, 8, .	5.6	35
2	Serum interferon- $\hat{1}\pm$ levels and IFN type I-stimulated genes score perform equally to assess systemic lupus erythematosus disease activity. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 901-903.	0.5	11
3	Pre-COVID-19 Immunity to Common Cold Human Coronaviruses Induces a Recall-Type IgG Response to SARS-CoV-2 Antigens Without Cross-Neutralisation. <i>Frontiers in Immunology</i> , 2022, 13, 790334.	2.2	10
4	Pulmonary Alveolar Proteinosis and Multiple Infectious Diseases in a Child with Autosomal Recessive Complete IRF8 Deficiency. <i>Journal of Clinical Immunology</i> , 2022, 42, 975-985.	2.0	7
5	Memory CD4+ T-Cell Lymphocytic Angiopathy in Fatal Forms of COVID-19 Pulmonary Infection. <i>Frontiers in Immunology</i> , 2022, 13, 844727.	2.2	2
6	The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2200413119.	3.3	110
7	Identification of bronchoalveolar and blood immune-inflammatory biomarker signature associated with poor 28-day outcome in critically ill COVID-19 patients. <i>Scientific Reports</i> , 2022, 12, .	1.6	12
8	Phenotypic Heterogeneity of Fulminant COVID-19-Related Myocarditis in Adults. <i>Journal of the American College of Cardiology</i> , 2022, 80, 299-312.	1.2	20
9	Improvement of HIV-associated neurocognitive disorders after antiretroviral therapy intensification: the Neuro+3 study. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 743-752.	1.3	10
10	IgA dominates the early neutralizing antibody response to SARS-CoV-2. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	840
11	Plasma Exchange to Rescue Patients with Autoantibodies Against Type I Interferons and Life-Threatening COVID-19 Pneumonia. <i>Journal of Clinical Immunology</i> , 2021, 41, 536-544.	2.0	62
12	Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers. <i>Nature Communications</i> , 2021, 12, 844.	5.8	146
13	Considering Personalized Interferon Beta Therapy for COVID-19. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	9
14	Perturbed Microbiota/Immune Homeostasis in Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, e997.	3.1	15
15	Beneficial role of <i>Pistacia lentiscus</i> aqueous extract in experimental colitis: anti-inflammatory and potential therapeutic effects. <i>Inflammopharmacology</i> , 2021, 29, 1225-1239.	1.9	7
16	Longitudinal Cytokine Profiling in Patients with Severe COVID-19 on Extracorporeal Membrane Oxygenation and Hemoadsorption. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 1433-1435.	2.5	23
17	High Th2 cytokine levels and upper airway inflammation in human inherited T-bet deficiency. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	25
18	Plasma neurofilament light chain predicts cerebellar atrophy and clinical progression in spinocerebellar ataxia. <i>Neurobiology of Disease</i> , 2021, 153, 105311.	2.1	39

#	ARTICLE	IF	CITATIONS
19	Distinct cytokine profiles associated with COVID-19 severity and mortality. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 2098-2107.	1.5	47
20	Tocilizumab in COVID-19 therapy: who benefits, and how?. <i>Lancet, The</i> , 2021, 398, 299-300.	6.3	6
21	Impaired respiratory burst contributes to infections in PKC ζ -deficient patients. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	23
22	Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. <i>Science Immunology</i> , 2021, 6, .	5.6	357
23	Plasma NFL levels and longitudinal change rates in <i>C9orf72</i> and <i>GRN</i> -associated diseases: from tailored references to clinical applications. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1278-1288.	0.9	25
24	Elevated Neopterin Levels Predict Fatal Outcome in SARS-CoV-2-Infected Patients. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 709893.	1.8	14
25	CD8+PD-L1+CXCR3+ polyfunctional T cell abundances are associated with survival in critical SARS-CoV-2-infected patients. <i>JCI Insight</i> , 2021, 6, .	2.3	16
26	LOX-1-Expressing Immature Neutrophils Identify Critically-Ill COVID-19 Patients at Risk of Thrombotic Complications. <i>Frontiers in Immunology</i> , 2021, 12, 752612.	2.2	14
27	Monoclonal antibody-mediated neutralization of SARS-CoV-2 in an IRF9-deficient child. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	24
28	Reply. <i>Arthritis and Rheumatology</i> , 2020, 72, 197-197.	2.9	0
29	Identification of peptides interfering with the LRRK2/PP1 interaction. <i>PLoS ONE</i> , 2020, 15, e0237110.	1.1	10
30	Human IgA binds a diverse array of commensal bacteria. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	65
31	Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. <i>Science</i> , 2020, 370, .	6.0	1,749
32	Autoantibodies against type I IFNs in patients with life-threatening COVID-19. <i>Science</i> , 2020, 370, .	6.0	1,983
33	Systemic chloroquine intoxication: a hint from the peripheral blood smear. <i>American Journal of Hematology</i> , 2020, 95, 873-875.	2.0	2
34	Ultrasensitive serum interferon- β quantification during SLE remission identifies patients at risk for relapse. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1669-1676.	0.5	59
35	Reverse Immunology Approach to Define a New HIV-gp41-Neutralizing Epitope. <i>Journal of Immunology Research</i> , 2019, 2019, 1-13.	0.9	3
36	THU0227...BIOLOGICAL MONITORING OF REMISSION IN SYSTEMIC LUPUS ERYTHEMATOSUS: ABNORMAL SERUM INTERFERON-ALPHA LEVELS PREDICT RELAPSE. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
37	Synergistic convergence of microbiota-specific systemic IgG and secretory IgA. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1575-1585.e4.	1.5	86
38	Monitoring Disease Activity in Systemic Lupus Erythematosus With Single-Molecule Array Digital Enzyme-Linked Immunosorbent Assay Quantification of Serum Interferon- γ . <i>Arthritis and Rheumatology</i> , 2019, 71, 756-765.	2.9	51
39	Microbial ecology perturbation in human IgA deficiency. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	206
40	Assessment of an ultra-sensitive IFN γ immunoassay prototype for latent tuberculosis diagnosis. <i>European Cytokine Network</i> , 2018, 29, 136-145.	1.1	0
41	Generating Chemokine Analogs with Enhanced Pharmacological Properties Using Phage Display. <i>Methods in Enzymology</i> , 2016, 570, 47-72.	0.4	6
42	Involvement of NK Cells and Nkp30 Pathway in Antisynthetase Syndrome. <i>Journal of Immunology</i> , 2016, 197, 1621-1630.	0.4	26
43	ECL1i, d(LGTFLKC), a novel, small peptide that specifically inhibits CCL2-dependent migration. <i>FASEB Journal</i> , 2016, 30, 2370-2381.	0.2	27
44	Gene transfer of two entry inhibitors protects CD4+ T cell from HIV-1 infection in humanized mice. <i>Gene Therapy</i> , 2016, 23, 144-150.	2.3	13
45	Identification of the Single Immunodominant Region of the Native Human CC Chemokine Receptor 6 Recognized by Mouse Monoclonal Antibodies. <i>PLoS ONE</i> , 2016, 11, e0157740.	1.1	2
46	Ultraviolet light converts propranolol, a nonselective β -blocker and potential lupus-inducing drug, into a proinflammatory AhR ligand. <i>European Journal of Immunology</i> , 2015, 45, 3174-3187.	1.6	36
47	HIV-Infected Spleens Present Altered Follicular Helper T Cell (Tfh) Subsets and Skewed B Cell Maturation. <i>PLoS ONE</i> , 2015, 10, e0140978.	1.1	49
48	Targeting Both Viral and Host Determinants of Human Immunodeficiency Virus Entry, Using a New Lentiviral Vector Coexpressing the T20 Fusion Inhibitor and a Selective CCL5 Intrakine. <i>Human Gene Therapy Methods</i> , 2014, 25, 232-240.	2.1	7
49	Pharmacological Inhibition of the Chemokine Receptor, CX3CR1, Reduces Atherosclerosis in Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 2297-2305.	1.1	65
50	CX3CR1 reduces Ly6Chigh-monocyte motility within and release from the bone marrow after chemotherapy in mice. <i>Blood</i> , 2013, 122, 674-683.	0.6	63
51	Identification of a cellular ligand for the natural cytotoxicity receptor NKp44. <i>Blood</i> , 2013, 122, 2935-2942.	0.6	144
52	Specific Targeting of Caspase-9/PP2A Interaction as Potential New Anti-Cancer Therapy. <i>PLoS ONE</i> , 2013, 8, e60816.	1.1	28
53	Role of CX3CR1 Receptor in Monocyte/Macrophage Driven Neovascularization. <i>PLoS ONE</i> , 2013, 8, e57230.	1.1	34
54	Activated and resting regulatory T cell exhaustion concurs with high levels of interleukin-22 expression in systemic sclerosis lesions. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1227-1234.	0.5	90

#	ARTICLE	IF	CITATIONS
55	CD4+ T Cell Depletion in Human Immunodeficiency Virus (HIV) Infection: Role of Apoptosis. <i>Viruses</i> , 2011, 3, 586-612.	1.5	106
56	Multiparameter grouping delineates heterogeneous populations of human IL-17 and/or IL-22 T cell producers that share antigen specificities with other T cell subsets. <i>European Journal of Immunology</i> , 2011, 41, 2596-2605.	1.6	19
57	CCL20 and Î²-Defensin-2 Induce Arrest of Human Th17 Cells on Inflamed Endothelium In Vitro under Flow Conditions. <i>Journal of Immunology</i> , 2011, 186, 1411-1420.	0.4	64
58	Exhausted Cytotoxic Control of Epstein-Barr Virus in Human Lupus. <i>PLoS Pathogens</i> , 2011, 7, e1002328.	2.1	111
59	Subtle conformational changes between CX3CR1 genetic variants as revealed by resonance energy transfer assays. <i>FASEB Journal</i> , 2010, 24, 4585-4598.	0.2	12
60	Abstract 2361: Fractalkine and CX3CR1 are involved in the early stages of skeletal metastasis. , 2010, , .		0
61	An engineered CX3CR1 antagonist endowed with anti-inflammatory activity. <i>Journal of Leukocyte Biology</i> , 2009, 86, 903-911.	1.5	67
62	Engineered CCR5 superagonist chemokine as adjuvant in anti-tumor DNA vaccination. <i>Vaccine</i> , 2008, 26, 3252-3260.	1.7	16
63	Prominent Plasmacytosis Following Intravenous Immunoglobulin Correlates with Clinical Improvement in Guillain-Barré Syndrome. <i>PLoS ONE</i> , 2008, 3, e2109.	1.1	17
64	The immune paradox of sarcoidosis and regulatory T cells. <i>Journal of Experimental Medicine</i> , 2006, 203, 359-370.	4.2	392
65	Global Natural Regulatory T Cell Depletion in Active Systemic Lupus Erythematosus. <i>Journal of Immunology</i> , 2005, 175, 8392-8400.	0.4	416
66	Immunogenicity of HIV Type 1 gp120 CD4 Binding Site Phage Mimotopes. <i>AIDS Research and Human Retroviruses</i> , 2005, 21, 82-92.	0.5	31
67	Phage-displayed libraries of peptide/major histocompatibility complexes. <i>European Journal of Immunology</i> , 2004, 34, 598-607.	1.6	10
68	Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. <i>Oncogene</i> , 2003, 22, 660-664.	2.6	179
69	Human Immunodeficiency Virus Type 1 Entry Inhibitors Selected on Living Cells from a Library of Phage Chemokines. <i>Journal of Virology</i> , 2003, 77, 6637-6644.	1.5	49